Literature DB >> 12718604

Helicobacter Pylori Seropositivity, the Interleukin 1B Polymorphism, and Smoking among First-visit Outpatients.

Nobuyuki Hamajima1, Hidemi Ito, Keitaro Matsuo, Kazuo Tajima, Suketami Tominaga.   

Abstract

Our previous studies of 241 re-visit outpatients in the Helicobacter pylori (HP) eradication program (HPE) of Aichi Cancer Center Hospital (Jpn J Cancer Res 2001;92:383-389 ) and of 462 health checkup examinees (HCE) in Nagoya (Jpn J Public Health 2001;48:604-612) found a significant association between HP seropositivity and the Interleukin 1B (IL-1B) C-31T genotype, especially among current smokers. This study aimed to confirm the association for 547 first-visit outpatients (277 males and 270 females) of Aichi Cancer Center Hospital aged 40 to 79 years. Samples were genotyped by polymerase chain reaction with confronting two-pair primers (PCR-CTPP), the same method as that used in the previous studies. Sex-age-adjusted odds ratio (aOR) was 1.32 (95% confidence interval, 0.84-2.08) for CT genotype and 1.35 (0.84-2.08) for TT genotype. The aOR was higher in never smokers (aOR=1.69, 0.86-3.32 for TT genotype) than in current smokers (aOR=1.01, 0.34-2.98 for TT genotype). The obtained aORs for TT genotype were inconsistent to those in our previous studies; aOR=2.46 (1.06-5.74) for 241 HPE, aOR=1.74 (1.05-2.89) for 462 HCE, aOR=22.9 (1.97-266) for 55 HPE current smokers, and aOR=4.62 (0.94-22.7) for 67 HCE current smokers. Since the 95% confidence intervals of aORs for TT genotype from the three study subjects overlapped, the inconsistent findings could be due to random errors. Alternatively, there might be other effect modifiers for the association with the polymorphism. Further studies will be required to elucidate the causes of the observed inconsistent findings.

Entities:  

Year:  2002        PMID: 12718604

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  5 in total

1.  Helicobacter pylori-induced miR-135b-5p promotes cisplatin resistance in gastric cancer.

Authors:  Linlin Shao; Zheng Chen; Mohammed Soutto; Shoumin Zhu; Heng Lu; Judith Romero-Gallo; Richard Peek; Shutian Zhang; Wael El-Rifai
Journal:  FASEB J       Date:  2018-07-09       Impact factor: 5.191

2.  Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A.

Authors:  Yoshiko Ishida; Yasuyuki Goto; Takaaki Kondo; Mio Kurata; Kazuko Nishio; Sayo Kawai; Tomo Osafune; Mariko Naito; Nobuyuki Hamajima
Journal:  Int J Med Sci       Date:  2006-09-10       Impact factor: 3.738

3.  No association between angiotensin I converting enzyme (ACE) I/D polymorphism and gastric cancer risk among Japanese.

Authors:  Satoshi Hibi; Yasuyuki Goto; Takafumi Ando; Keitaro Matsuo; Kenji Wakai; Kazuo Tajima; Hidemi Goto; Nobuyuki Hamajima
Journal:  Nagoya J Med Sci       Date:  2011-08       Impact factor: 1.131

4.  Associations between cytokine gene polymorphisms and susceptibility to Helicobacter pylori infection and Helicobacter pylori related gastric cancer, peptic ulcer disease: A meta-analysis.

Authors:  Jingjing Ma; Dandan Wu; Xue Hu; Jiao Li; Mingwei Cao; Weiguo Dong
Journal:  PLoS One       Date:  2017-04-28       Impact factor: 3.240

5.  Demographics and Clinical and Endoscopic Characteristics of Patients with Helicobacter pylori Infection and Gastroesophageal Reflux Disease: A Case-Control Study.

Authors:  Amir Mari; Naim Mahroum; Nicola Luigi Bragazzi; Mahran Shalaata; Tawfik Khoury; Abdulla Watad; Mahmud Mahamid
Journal:  Gastroenterol Res Pract       Date:  2019-05-06       Impact factor: 2.260

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.